Online citations, reference lists, and bibliographies.
← Back to Search

Immune Microenvironment Of Primary And Recurrent Craniopharyngiomas: A Study Of The Differences And Clinical Significance.

D. Lin, Y. Wang, Z. Zhou, Z. Lin
Published 2019 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
OBJECTIVE This study explored the differences between the immune microenvironments of primary and recurrent craniopharyngiomas (CPs). In addition, we investigated the relationship between the immune microenvironment and clinical characteristics of CP. METHODS We collected 52 specimens from 26 patients with CPs. For each patient, specimens for both primary and recurrent CPs were obtained. We performed an immunohistochemical analysis of these specimens to determine the distributions of M2 macrophages, CD8+ T cells, programmed cell death 1 ligand 1 (PD-L1), and Ki67. RESULTS In recurrent CP specimens, the distributions of M2 macrophages, Ki67, and PD-L1 increased compared with primary CP specimens (P = 0.019, P = 0.0084, and P = 0.0319, respectively). Moreover, the distributions of M2 macrophages, CD8+ T cells, and PD-L1 in papillary CPs were higher than those observed in adamantinomatous craniopharyngiomas (ACPs) (P = 0.0317, P = 0.0359, and P < 0.0001, respectively). In the adult ACP group, M2 macrophages, CD8+ T cells, and PD-L1 were more abundant/expressed than in the child ACP group (P = 0.0159, P = 0.0215, and P < 0.0088, respectively). A positive correlation was found between M2 macrophages and CD8+ T cells (r = 0.4079; P = 0.0027). Correspondingly, M2 macrophages and CD8+ T cells were both positively correlated with PD-L1 (r = 0.4564; P = 0.0007 and r = 0.3987; P = 0.0034, respectively). The observed high expression of M2 macrophages in primary CPs suggests a shortened time for tumor recurrence (P = 0.0131). CONCLUSIONS The microenvironment of recurrent CP varies from that of primary CP. The abundance of M2 macrophages in primary CP may indicate a risk of early recurrence. Therefore, it is recommended to increase the frequency of follow-up examinations in these patients.
This paper references
10.1016/S0140-6736(17)31827-5
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Y. Kang (2017)
10.3390/cancers6031670
Tumor-Associated Macrophages as Major Players in the Tumor Microenvironment
Theerawut Chanmee (2014)
10.1093/jnen/nlx061
Molecular Analyses Reveal Inflammatory Mediators in the Solid Component and Cyst Fluid of Human Adamantinomatous Craniopharyngioma
A. Donson (2017)
The Effects of Schwann and Bone Marrow Stromal Stem Cells on Sciatic Nerve Injury in Rat: A Comparison of Functional Recovery
S. Zarbakhsh (2012)
10.1038/nrendo.2016.217
New outlook on the diagnosis, treatment and follow-up of childhood-onset craniopharyngioma
H. Müller (2017)
10.1016/j.ccr.2014.05.016
Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy.
C. Ries (2014)
10.3171/JNS.1999.90.2.0237
Surgical treatment of craniopharyngiomas: experience with 168 patients.
R. Fahlbusch (1999)
10.3340/jkns.2015.0707.022
Malignant Transformation of Craniopharyngioma without Radiation Therapy: Case Report and Review of the Literature
T. S. Jeong (2017)
10.1016/j.cell.2010.03.014
Macrophage Diversity Enhances Tumor Progression and Metastasis
Bin-Zhi Qian (2010)
10.1136/jnnp.2003.012781
Correlation between clinical characteristics and proliferative activity in patients with craniopharyngioma
M. Losa (2004)
10.1093/neuonc/noy035
Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma
S. Coy (2018)
10.3171/jns.1998.89.4.0547
The descriptive epidemiology of craniopharyngioma.
G. Bunin (1997)
10.1158/2159-8290.CD-13-0310
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.
E. Akbay (2013)
10.3171/JNS.1990.73.1.0012
Correlation of clinical and pathological features in surgically treated craniopharyngiomas.
T. E. Adamson (1990)
10.1038/nm.3337
CSF-1R inhibition alters macrophage polarization and blocks glioma progression
S. Pyonteck (2013)
10.1038/nm730
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
H. Dong (2002)
10.1038/nm.3394
Microenvironmental regulation of tumor progression and metastasis
Daniela F. Quail (2013)
10.1073/pnas.0611533104
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer
J. Hamanishi (2007)
10.1056/NEJMoa1613493
First‐Line Nivolumab in Stage IV or Recurrent Non–Small‐Cell Lung Cancer
D. Carbone (2017)
10.1007/s003810100458
Radical excision of pediatric craniopharyngioma: recurrence pattern and prognostic factors
S. Kim (2001)
10.3171/2016.9.FOCUS16315
Management and outcome of recurrent adult craniopharyngiomas: an analysis of 42 cases with long-term follow-up.
M. Turel (2016)
10.3892/ijmm.3.2.157
Prognostic significance of the MIB-1 labeling index for patient with craniopharyngioma.
T. Nishi (1999)
10.1038/s41598-017-13942-8
Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues
E. Parra (2017)
10.1007/s00381-017-3473-3
A reformed surgical treatment modality for children with giant cystic craniopharyngioma
Wanchun Zhu (2017)
10.1016/j.wneu.2012.07.033
Predictive factors for craniopharyngioma recurrence: a systematic review and illustrative case report of a rapid recurrence.
R. Prieto (2013)
10.1016/j.ccell.2017.02.009
The Microenvironmental Landscape of Brain Tumors.
Daniela F. Quail (2017)
10.1016/S1470-2045(15)70054-9
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.
N. Rizvi (2015)
10.1097/PPO.0000000000000299
Clinical Development of PD-1 in Advanced Melanoma
R. Munhoz (2018)
10.1093/jnci/djv310
Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy.
P. Brastianos (2016)
10.1016/j.wneu.2017.02.095
Outcome of Radical Surgical Resection for Craniopharyngioma with Hypothalamic Preservation: A Single-Center Retrospective Study of 1054 Patients.
X. Shi (2017)
10.3171/2016.9.FOCUS16325
Diagnosis and management of craniopharyngiomas in the era of genomics and targeted therapy.
J. C. Martinez-Gutierrez (2016)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar